During my doctoral studies, I specialized in two areas of research: tumor-targeted therapy utilizing bacterial toxins and the pathogenic mechanisms of pathogenic microorganisms. I have a profound interest in elucidating the role of microbial communities in various diseases and their potential as therapeutic targets. Currently, my research focuses on investigating the interplay between the gut microbiota and the immune system concerning autism spectrum disorder, aiming to provide valuable insights for therapeutic interventions. Additionally, I am deeply intrigued by the field of bioinformatics.
Previous publications：
1. Chang Jiang, Liu Xilin, Ren Honglin, et al. Pseudomonas Exotoxin A‑Based Immunotherapy Targeting CCK2R-Expressing Colorectal Malignancies: An In Vitro and In Vivo Evaluation, Molecular Pharmaceutics, 2021,7;18(6):2285-2297.
2. Chang Jiang, Zou Deying, Ren Honglin, et al. An ultrasensitive and long-lasting chemiluminescence immunoassay for IP-10 detection based on a 4-bromophenol-reinforced bienzymatic system[J]. Microchemical Journal, 2022, 181: 107719.
3. Chang Jiang, Liu Zengshan, Song Defeng, et al. Cholecystokinin type 2 receptor in colorectal cancer: diagnostic and therapeutic target. Journal of Cancer Research and Clinical Oncology, 2020,146(9):2205-2217.
4. Chang Jiang, Hou Xusen, Yang Xin, et al. A rapid and sensitive triplex-recombinase polymerase amplification for simultaneous differentiation of Brucella abortus, Brucella melitensis, and Brucella suis in sera and foods. FEMS Microbiol Lett. 2023;370:fnad056.
5. Zou Deying1, Chang Jiang1, Lu Shiying1, et al.Analysis of virulence proteins in pathogenic Acinetobacter baumannii to provide early warning of zoonotic risk. Microbiological Research. 2022, 266: 127222.
6. Guo Xun1, ChangJiang1, Lu Shying1, et al. Multiantigen epitope fusion recombinant proteins from capsids of serotype 4 fowl adenovirus induce chicken immunity against avian Angara disease. Vet Microbiol. 2023 Mar;278:109661
7. Li Meng1, Chang Jiang1, Ren Honglin1, et al. Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy. [J]. Current cancer drug targets, 2022, 22(3):257-268.
8. Peng Lixiong1, Chang Jiang1, Liu Xilin1, et al. MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer, Current Issues in Molecular Biology. 2021, 43: 1529-1547.